Articolul precedent |
Articolul urmator |
377 2 |
Ultima descărcare din IBN: 2024-01-24 16:30 |
SM ISO690:2012 CHILARI, Mihaela, CHIANU, Marin. Sindromul neuroleptic malign la utilizarea neurolepticelor Atipice în tratamentul schizofreniei. In: Congresul consacrat aniversării a 75-a de la fondarea Universității de Stat de Medicină şi Farmacie „Nicolae Testemiţanu”, 21-23 octombrie 2020, Chişinău. Chişinău: USMF, 2020, p. 333. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Congresul consacrat aniversării a 75-a de la fondarea Universității de Stat de Medicină şi Farmacie „Nicolae Testemiţanu” 2020 | ||||||
Congresul "Congresul consacrat aniversării a 75-a de la fondarea Universității de Stat de Medicină şi Farmacie „Nicolae Testemiţanu”" Chişinău, Moldova, 21-23 octombrie 2020 | ||||||
|
||||||
Pag. 333-333 | ||||||
|
||||||
Descarcă PDF | ||||||
Rezumat | ||||||
Background. Neuroleptic malignant syndrome (NMS) as an adverse reaction to the use of atypical neuroleptics (AN) is present in 0.02 - 3 % of patients, being determined by age, sex, diagnosis and the group of atypical neuroleptics that were administered. Objective of the study. Analysis and systematization of the adverse reactions (neuroleptic malignant syndrome) produced by atypical neuroleptics. Material and Methods. The articles from the PubMed and MEDLINE database were selected and analyzed according to the keywords “neuroleptic malignant syndrome”, “atypical antipsychotic drugs”, “treatment of schizophrenia”. Results. He pathophysiology of this adverse reaction is not fully elucidated, a hypothesis is the rapid blockade of D2 receptors in the CNS. NMS includes such symptoms as: instability, extrapyramidal disorders, hyperpyrexia, and altered mental state. When using AN as clozapine, risperidone, olanzapine and quentiapine SNM occurred on average on the 14th day. Thus, on the background of the treatment with clozapine SNM was manifested in 30%, in the administration of risperidone in 38%, in the administration of olanzapine in 27%, and quentiapine in 5% of cases. Conclusion. Thus, we can say that in terms of treatment with AN, the SNM rate is lower than with the use of typical neuroleptics or it may simply be a reflection of doctors' awareness and the followup of early treatment with more harmless and contemporary drugs. |
||||||
Cuvinte-cheie neuroleptic malignant syndrome, atypical neuroleptics, sindrom neuroleptic malign, neuroleptice atipice |
||||||
|